These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 21376394)
1. Translocation t(1;9) is a recurrent cytogenetic abnormality associated with progression of essential thrombocythemia patients displaying the JAK2 V617F mutation. Leon A; Staropoli JF; Hernandez JM; Longtine JA; Kuo FC; Dal Cin P Leuk Res; 2011 Sep; 35(9):1188-92. PubMed ID: 21376394 [TBL] [Abstract][Full Text] [Related]
2. Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development. Ohyashiki K; Kodama A; Ohyashiki JH Cancer Genet Cytogenet; 2008 Oct; 186(1):6-11. PubMed ID: 18786436 [TBL] [Abstract][Full Text] [Related]
3. A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis. Larsen TS; Hasselbalch HC; Pallisgaard N; Kerndrup GB Cancer Genet Cytogenet; 2007 Jan; 172(2):107-12. PubMed ID: 17213018 [TBL] [Abstract][Full Text] [Related]
4. JAK2 V617F-positive essential thrombocythemia in a patient with Klinefelter syndrome: a case report. Yhim HY; Kim HS; Sohn JY; Song MJ; Lee NR; Song EK; Choi SI; Yim CY; Kwak JY Cancer Genet Cytogenet; 2010 Apr; 198(2):162-5. PubMed ID: 20362232 [TBL] [Abstract][Full Text] [Related]
5. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia. Hsiao HH; Ito Y; Sashida G; Ohyashiki JH; Ohyashiki K Leuk Res; 2005 Nov; 29(11):1247-52. PubMed ID: 16164981 [TBL] [Abstract][Full Text] [Related]
6. A gain-of-function mutation of JAK2 in myeloproliferative disorders. Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187 [TBL] [Abstract][Full Text] [Related]
7. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. Gangat N; Tefferi A; Thanarajasingam G; Patnaik M; Schwager S; Ketterling R; Wolanskyj AP Eur J Haematol; 2009 Jul; 83(1):17-21. PubMed ID: 19236446 [TBL] [Abstract][Full Text] [Related]
8. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis. Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192 [TBL] [Abstract][Full Text] [Related]
9. Reemergence of JAK2 V617F clone heralds extramedullary leukemia relapse after BMT for transformed essential thrombocytosis. Au WY; Fung A; Lie AK; Lam KY; Lam CC; Kwong YL Ann Hematol; 2007 Feb; 86(2):145-7. PubMed ID: 17111143 [No Abstract] [Full Text] [Related]
10. Derivative (1;18)(q10;q10) in essential thrombocythemia. Azuma T; Yamanouchi J; Inoue K; Kohno M; Narumi H; Fujiwara H; Yakushijin Y; Hato T; Yasukawa M Cancer Genet Cytogenet; 2010 May; 199(1):62-4. PubMed ID: 20417872 [TBL] [Abstract][Full Text] [Related]
11. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600 [TBL] [Abstract][Full Text] [Related]
13. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T; Ann Hematol; 2010 Feb; 89(2):141-6. PubMed ID: 19582452 [TBL] [Abstract][Full Text] [Related]
14. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome]. Brière J Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652 [TBL] [Abstract][Full Text] [Related]
15. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940 [TBL] [Abstract][Full Text] [Related]
16. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders. Musolino C; Allegra A; Penna G; Centorrino R; Cuzzola M; D'Angelo A; Iacopino P; Alonci A Acta Haematol; 2009; 122(1):46-9. PubMed ID: 19816006 [TBL] [Abstract][Full Text] [Related]